OptimizeRx Corp. announced robust financial results for the fourth quarter and full year ended December 31, 2024. Fourth-quarter revenue reached $32.32 million, marking a 14% increase year-over-year and surpassing the consensus estimate of $30.36 million.
The company reported adjusted earnings per share (EPS) of $0.30 for Q4, exceeding analyst estimates of $0.27. For the full year 2024, revenue grew 29% year-over-year to $92.1 million, with adjusted EBITDA increasing 53% in Q4 to $8.8 million and reaching $11.7 million for the full year.
OptimizeRx provided its full-year 2025 guidance, projecting revenue of at least $100 million and adjusted EBITDA of at least $12 million. The company also highlighted its strategic focus on transitioning Dynamic Audience Activation Platform (DAAP) customers to a subscription-based model for data services, aiming to improve margins and increase revenue predictability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.